Garside Surgery Limited 07177215 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is that of the provision of urology services. Digita Accounts Production Advanced 6.30.9574.0 true true 07177215 2023-04-01 2024-03-31 07177215 2024-03-31 07177215 core:RetainedEarningsAccumulatedLosses 2024-03-31 07177215 core:ShareCapital 2024-03-31 07177215 core:CurrentFinancialInstruments 2024-03-31 07177215 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 07177215 core:FurnitureFittingsToolsEquipment 2024-03-31 07177215 core:MotorVehicles 2024-03-31 07177215 bus:SmallEntities 2023-04-01 2024-03-31 07177215 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 07177215 bus:FullAccounts 2023-04-01 2024-03-31 07177215 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 07177215 bus:RegisteredOffice 2023-04-01 2024-03-31 07177215 bus:Director4 2023-04-01 2024-03-31 07177215 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 07177215 core:FurnitureFittings 2023-04-01 2024-03-31 07177215 core:FurnitureFittingsToolsEquipment 2023-04-01 2024-03-31 07177215 core:MotorVehicles 2023-04-01 2024-03-31 07177215 core:PlantMachinery 2023-04-01 2024-03-31 07177215 countries:EnglandWales 2023-04-01 2024-03-31 07177215 2023-03-31 07177215 core:FurnitureFittingsToolsEquipment 2023-03-31 07177215 core:MotorVehicles 2023-03-31 07177215 2022-04-01 2023-03-31 07177215 2023-03-31 07177215 core:RetainedEarningsAccumulatedLosses 2023-03-31 07177215 core:ShareCapital 2023-03-31 07177215 core:CurrentFinancialInstruments 2023-03-31 07177215 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 07177215 core:FurnitureFittingsToolsEquipment 2023-03-31 07177215 core:MotorVehicles 2023-03-31 iso4217:GBP xbrli:pure

Registration number: 07177215

Garside Surgery Limited

Unaudited Financial Statements

for the Year Ended 31 March 2024

 

Garside Surgery Limited

Contents

Statement of Financial Position

1

Notes to the Unaudited Financial Statements

2 to 4

 

Garside Surgery Limited

(Registration number: 07177215)
Statement of Financial Position as at 31 March 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

20,763

29,475

Current assets

 

Debtors

5

25,312

27,307

Cash at bank and in hand

 

257,724

147,740

 

283,036

175,047

Creditors: Amounts falling due within one year

6

(66,604)

(52,137)

Net current assets

 

216,432

122,910

Total assets less current liabilities

 

237,195

152,385

Provisions for liabilities

(5,191)

(7,369)

Net assets

 

232,004

145,016

Capital and reserves

 

Called up share capital

110

110

Retained earnings

231,894

144,906

Shareholders' funds

 

232,004

145,016

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 27 November 2024 and signed on its behalf by:
 

Dr N Oakley
Director

   
     
 

Garside Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
319 Fulwood Road
Sheffield
S10 3BJ

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Garside Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

25% of net book value

Motor Vehicles

20% on cost

Fixtures and fittings

25% on cost

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2023 - 4).

 

Garside Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 April 2023

20,026

35,512

55,538

At 31 March 2024

20,026

35,512

55,538

Depreciation

At 1 April 2023

13,634

12,429

26,063

Charge for the year

1,610

7,102

8,712

At 31 March 2024

15,244

19,531

34,775

Carrying amount

At 31 March 2024

4,782

15,981

20,763

At 31 March 2023

6,392

23,083

29,475

5

Debtors

Note

2024
£

2023
£

Amounts owed by Manchester Urology LLP

21,064

25,216

Other debtors

 

4,248

2,091

 

25,312

27,307

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

63,783

45,877

Accruals and deferred income

2,820

2,820

Other creditors

1

3,440

66,604

52,137